Why cured hep C patients still need monitoring

Direct-acting antivirals don't eliminate the risk of cancer, doctors warn

Patients are still at risk of recurrent hepatocellular carcinoma (HCC) after treatment with oral direct-acting antivirals (DAA), according to a systematic review and meta-analysis.

A 12 or 24-week regimen of oral DAAs clears hepatitis C and results in sustained viral response for most patients.